|
BBX expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.65650001995965E-09 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.34169999999045E-07 |
| Normal-vs-Stage2 |
1.798860E-04 |
| Normal-vs-Stage3 |
1.58790000037712E-08 |
| Normal-vs-Stage4 |
4.70000000030169E-08 |
| Stage1-vs-Stage2 |
9.183600E-01 |
| Stage1-vs-Stage3 |
2.334400E-01 |
| Stage1-vs-Stage4 |
7.284000E-02 |
| Stage2-vs-Stage3 |
4.800800E-01 |
| Stage2-vs-Stage4 |
2.658600E-01 |
| Stage3-vs-Stage4 |
5.308200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.25710003412638E-09 |
| Normal-vs-AfricanAmerican |
2.377800E-02 |
| Normal-vs-Asian |
6.34900000018312E-07 |
| Caucasian-vs-AfricanAmerican |
1.788750E-01 |
| Caucasian-vs-Asian |
4.945600E-01 |
| AfricanAmerican-vs-Asian |
9.765700E-02 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.38719999931425E-08 |
| Normal-vs-Female |
2.43640000396894E-08 |
| Male-vs-Female |
4.019200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
7.43370000000354E-07 |
| Normal-vs-Age(41-60Yrs) |
9.83100000295778E-08 |
| Normal-vs-Age(61-80Yrs) |
2.7441000027828E-08 |
| Normal-vs-Age(81-100Yrs) |
4.695800E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
6.961400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.720800E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.358000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.307200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.048200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.859200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.958650E-01 |
| Classical-VS-Follicular |
2.458000E-01 |
| Classical-VS-Other |
2.276400E-01 |
| Classical-VS-Normal |
1.27710000019654E-07 |
| Tall-VS-Follicular |
6.863400E-01 |
| Tall-VS-Other |
5.668600E-01 |
| Tall-VS-Normal |
2.64439999997368E-06 |
| Follicular-VS-Other |
5.292800E-01 |
| Follicular-VS-Normal |
2.58669999997352E-06 |
| Other-VS-Normal |
5.140100E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
4.15159999711534E-08 |
| Normal-vs-N1 |
3.01289999615761E-08 |
| N0-vs-N1 |
1.465420E-01 |
|
|
